A mix of quick wit, deep reflection, and comedic tension is coming to Spring Grove’s Ye Olde Opera House’s stage, as actors ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $8.00 price target on ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...

N.V. announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum and ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

(NYSE: FI), a leading global provider of payments and financial services technology, has published the Fiserv Small Business Index for February 2025, with the seasonally adjusted Index holding steady ...

Third Point LLC, an alternative investment manager, today announced that it has completed the previously announced acquisition of AS Birch Grove LP (“Birch Grove”), a diversified alternative credit ...

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...

[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...

“Shop in the name of love” is an answer in a Sunday crossword that I remember from long ago, before I started in the biz myself. The clue for it was, “Buy some Valentine cards.” Perhaps ...

A NEW retrospective study from Japan has provided real-world insights into the efficacy and safety of avacopan, an oral C5a receptor antagonist, for antineutrophil cytoplasmic antibody ...

About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover ...